Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Osimertinib, Cetuximab, and Tucatinib in Advanced EGFR-Mutant NSCLC With Acquired Resistance to Osimertinib

NCT06067776 is registered in ClinicalTrials.gov with Jonathan Riess as lead sponsor.

NCT NCT06067776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06067776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Osimertinib, Cetuximab, and Tucatinib in Advanced EGFR-Mutant NSCLC With Acquired Resistance to Osimertinib
Lead sponsor
Jonathan Riess
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 1, 2024
Completion date
November 1, 2026
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic lung non-small cell carcinoma, recurrent lung non-small cell carcinoma, stage iv lung cancer ajcc v8